Table 4.
Studies of use of peptide receptor radionuclide therapy (PRRT) in neuroendocrine liver metastases.
| Author | Year | Tumor Type | N | PNET (N) | Rx Arm | Sx Resp (%) | BC Resp (%) | Imaging Response (%) | Morbidity (%) | Mortality (%) | Median PFS/TTP (mo) | Median OS/DSS (mo) | Five-Year Survival (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR+PR | SD | PD | |||||||||||||
| Valkema [80] | 2006 | GEPNET | 58 | ≥14 | - | 58 | 9 | 62 | 29 | 20 | 8 | 14/- | 37/- | - | |
| Kwekkeboom [79] | 2008 | GEPNET | 310 | ≥79 | - | - | - | 29 | 51 | 20 | 0.4 | - | 33/- | 46/- | - |
| Bodei [81] | 2011 | NET | 51 | 14 | - | - | - | 33 | 53 | 18 | - | 27 # | -/36 | nr/- | - |
| Ezziddin [82] | 2011 | GEPNET | 81 | 37 | - | - | - | 38 * | 46 * | 16 * | - | - | -/- | -/- | - |
| Ezzidddin [83] | 2011 | GEPNET | 42 | 12 | - | 100 ¥ | - | 72 | 38 | 12 | - | 0 | 35/- | 51/- | - |
| Bertani [78] | 2016 | PNET | 94 | 94 | - | - | - | 26 | 42 | 32 | - | - | 36/- | 76/- | - |
| Strosberg [84] | 2017 | GI NET | 111 | 0 | - | - | - | 18 | - | - | 0.9–9 | - | nr/- | nr/- | - |
| Partelli [85] | 2018 | PNET | 23 | 23 | PRRT first | - | - | 70 | 22 | 8 | 4 | - | 52/- | -/nr | - |
| PNET | 23 | 23 | Upfront surgery | - | - | - | - | - | - | - | 37/- | -/nr | - | ||
| Carlsen [86] | 2019 | GEPNET | 149 | 89 | - | - | - | 42 | 38 | 20 | 17 | - | 14/- | 29/- | - |
| Satapathy [87] | 2020 | NET | 45 | 14 | - | 75 | 50 | 30 | 55 | 15 | 2–4 | - | 48/- | 84/- | - |
| Sistani [88] | 2020 | NET | 47 | 13 | - | - | - | 32 | 53 | 15 | - | - | 36/- | nr/- | - |
| Kaemmerer [40] | 2021 | GEPNET | 486 | 148 | PT resection |
- | - | - | - | - | - | - | 18/- | 134/- | 71 |
| GEPNET | 403 | 187 | No PT resection |
- | - | - | - | - | - | - | 14/- | 67/- | 42 | ||
* SWOG tumor response criteria; # died from disease progression; ¥ denominator is patients with pain from osseous metastases; GEPNET, gastroenteropancreatic neuroendocrine tumor; NET, neuroendocrine tumor; PNET, pancreatic neuroendocrine tumor; GI NET, gastrointestinal neuroendocrine tumor; N, number of patients; Rx arm, treatment arm; Sx Resp, symptomatic response; BC Resp, biochemical response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; TTP, time to progression; OS, overall survival; DDS, disease specific survival; mo, months; nr, not reached; yr, year.